Comparative Pharmacology
Head-to-head clinical analysis: COMTAN versus ENTACAPONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMTAN versus ENTACAPONE.
COMTAN vs ENTACAPONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective and reversible inhibitor of catechol-O-methyltransferase (COMT), which inhibits the metabolism of levodopa to 3-O-methyldopa, thereby increasing the plasma half-life and bioavailability of levodopa in the brain.
Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), which inhibits the metabolism of levodopa to 3-O-methyldopa, thereby increasing the plasma half-life and bioavailability of levodopa in the brain.
200 mg orally once daily, increased to 200 mg three times daily as tolerated, with each dose of levodopa/carbidopa; maximum 200 mg per dose.
200 mg orally administered concomitantly with each dose of carbidopa/levodopa, up to a maximum of 8 times daily (1600 mg/day).
None Documented
None Documented
Clinical Note
moderateEntacapone + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Entacapone is combined with Fluticasone propionate."
Clinical Note
moderateEntacapone + Venlafaxine
"The risk or severity of adverse effects can be increased when Entacapone is combined with Venlafaxine."
Clinical Note
moderateEntacapone + Nefazodone
"The risk or severity of adverse effects can be increased when Entacapone is combined with Nefazodone."
Clinical Note
moderateTerminal elimination half-life is approximately 0.4 to 0.7 hours (mean 0.7 hours) in plasma, but the pharmacodynamic half-life (COMT inhibition) is longer, about 2-4 hours, supporting thrice-daily dosing.
Terminal elimination half-life is approximately 0.4–0.7 hours in the initial phase, with a terminal half-life of 2–2.5 hours, reflecting rapid elimination; clinically, entacapone is administered with each levodopa/carbidopa dose to inhibit COMT.
Primarily fecal (90%) as unchanged drug; renal excretion accounts for approximately 10%, mostly as glucuronide conjugates.
Primarily hepatic metabolism with biliary excretion: about 90% of dose excreted in feces, 10% in urine (as metabolites).
Category C
Category A/B
COMT Inhibitor
COMT Inhibitor
Entacapone + Stiripentol
"The risk or severity of adverse effects can be increased when Entacapone is combined with Stiripentol."